Dexcom Stelo and Abbott Lingo Made ‘Blood Sugar Spikes’ a Lifestyle Problem—But Here’s the Measurement Trick That Can Make Your “Healthy” Breakfast Look Dangerous
OTC CGMs turned glucose into a consumer score—and “spikes” into a designed event, not a universal medical fact. The trick: app-defined thresholds and proprietary algorithms can make normal post-meal rises feel like failure.
Key Points
- 1Track the regulatory shift: FDA-cleared OTC CGMs (Dexcom Stelo, Abbott Lingo) moved glucose monitoring from prescription medicine into retail wellness.
- 2Recognize the measurement trick: “blood sugar spikes” aren’t universal—apps often define them with proprietary thresholds, algorithms, and score-based storytelling.
- 3Use CGMs for patterns, not punishment: focus on repeatable trends with context, and remember Stelo isn’t designed to alert for dangerous lows.
A few years ago, wearing a continuous glucose monitor (CGM) without diabetes would have read as a niche biohacker flex—expensive, slightly eccentric, and hard to justify. In 2024, it became a mainstream retail decision.
The shift wasn’t cultural first. It was regulatory. On March 5, 2024, the FDA cleared Dexcom Stelo as the first over-the-counter (OTC) CGM in the United States. The label matters: adults 18+, not on insulin, and without problematic hypoglycemia, because the system is not designed to alert users to dangerous lows. On June 10, 2024, Abbott announced FDA clearance for two OTC CGM systems, including Lingo, positioned as a health and wellness glucose tracker for adults 18+ not on insulin. By late summer, the new category was no longer hypothetical: Dexcom said Stelo was available in the U.S. on Aug. 26, 2024, and Abbott said Lingo was available on Sept. 5, 2024.
A medical device, sold directly, recast as consumer feedback. The promise is seductively simple: wear a sensor, watch your blood sugar respond to breakfast, and “learn” what your body “likes.” Yet the most consequential change may be subtler. These products don’t just measure glucose. They teach people what to worry about.
“The real novelty isn’t that glucose rises after lunch. It’s that a phone app can turn that rise into a score—and a story about your self-control.”
— — TheMurrow (Pullquote)
The FDA’s green light, and the birth of an OTC CGM category
What Stelo is cleared for—and what it isn’t
Dexcom’s own positioning, echoed in coverage and the company’s materials, points toward three broad groups:
Who Dexcom positions Stelo for
- ✓People with type 2 diabetes not using insulin
- ✓People with prediabetes
- ✓People without diabetes who want to see how food and exercise affect glucose
That last category—the general consumer—is where the social story changes. A tool built for disease management becomes a tool for lifestyle governance.
Abbott enters with Lingo—and a split personality strategy
The dual-track strategy is revealing. Abbott didn’t simply bring a medical device to retail. It also separated “wellness” from “diabetes management” as different products with different narratives.
“2024 didn’t just bring new sensors. It brought a new idea: glucose as a wellness metric.”
— — TheMurrow (Pullquote)
From clinic to lifestyle: why the timing matters
CGMs as behavior-change tools: the official pitch
The logic is plausible, and it maps neatly onto how many people already treat sleep trackers or heart-rate data: not as definitive medical truth, but as a nudge.
The skeptical view: limited evidence, real psychological effects
Other experts quoted in popular press have raised a different concern: interpretation. Popular Science summarized worries that CGM data, when misunderstood, can fuel anxiety and misguided dietary restriction. That’s not speculation; it’s a known pattern in quantified-self culture. More data can mean more control—or more rumination.
“Numbers don’t automatically produce insight. Sometimes they produce worry.”
— — TheMurrow (Pullquote)
What counts as a “blood sugar spike”? Medicine vs. app logic
The result: a spike becomes whatever the app says it is.
There is no universal consumer definition
- Did the app flag this as a “spike”?
- Did my score worsen?
- What food “caused” it?
That shift isn’t trivial. Once a measurement becomes a score, it becomes moralized. “Good” and “bad” meals stop being metaphors and start looking like data.
Lingo’s “Spike” and the rise of proprietary thresholds
Lingo also acknowledges something many consumers overlook: a proprietary algorithm identifies “meaningful increases.” In other words, users are not merely seeing physiology; they’re seeing physiology filtered through product decisions.
Abbott’s own explainer blog offers a rare semi-quantitative hint about what might not register as a spike: fluctuations that stay below ~100 mg/dL and don’t rise faster than ~20 mg/dL within an hour “won’t be detected as a spike.” The caveat matters: this still doesn’t fully disclose the detection method. The point is not to litigate Abbott’s exact math. The point is that “spike” is a design choice, not a law of nature.
Key Insight
The promise—and the trap—of real-time feedback
Case study: the prediabetes user who wants proof
A CGM can supply what the clinic often cannot: immediate feedback. The user eats a bowl of cereal and watches glucose rise. The next day, they eat eggs and see a smaller bump. The device doesn’t just measure—it persuades, because it turns “eat better” into visible consequences.
That can be constructive. It can also be reductive, especially if the user begins to treat every rise as harm rather than normal physiology.
Case study: the wellness user who “eats to the graph”
The research record in the public conversation is cautious. Harvard Health’s “no solid evidence” line is the sober counterweight to the idea that every consumer will make better choices with a sensor. Some will. Others may simply become more anxious, more restrictive, or more confused.
Editor’s Note
What OTC CGMs can do well—when expectations are realistic
Practical takeaways for getting value without getting lost
- Meal composition effects: A mixed meal may show a different curve than a carb-heavy meal.
- Timing and activity: A walk after eating may change the trajectory.
- Repeatability: Seeing the same response across similar meals can be more informative than obsessing over one day.
The critical skill is interpretation. A single “spike” is not a diagnosis. A week of data is not the same as clinical testing. And an app’s score is not your pancreas’s report card.
Why the “no low-glucose alerts” detail matters for safety
That’s less a criticism than a reminder: these devices were cleared for specific populations. “OTC” doesn’t mean “for everyone.”
Safety Boundary
The debate: empowerment vs. over-medicalization
The empowerment argument
The FDA clearances and product launches are, at minimum, an acknowledgment that there is a legitimate consumer use case for seeing glucose trends—so long as the product is used within its labeled population.
The over-medicalization argument
A key tension sits inside the apps themselves. When companies define spikes with proprietary algorithms and convert them into a score like Lingo Count, they risk turning a complex biological signal into a behavioral morality play. Some users will thrive under that structure. Others will feel judged by a line graph.
“When companies define spikes with proprietary algorithms and convert them into a score, they risk turning biology into a behavioral morality play.”
— — TheMurrow (Pullquote)
How to think clearly before you buy
A short decision framework
Decision framework
- ✓Why am I wearing this? Prediabetes curiosity is different from general wellness optimization.
- ✓Am I likely to become anxious? If numbers tend to stress you, consider whether constant data will help.
- ✓Do I have a plan for interpretation? Ideally, pair patterns with context: meals, sleep, exercise, stress.
- ✓Am I in the intended population? The FDA clearance language exists to prevent misuse, not to annoy consumers.
What readers should watch next
A sensor can tell you what your glucose did. It can’t tell you who you are.
1) What is Dexcom Stelo, and who is it for?
2) What is Abbott Lingo, and how is it positioned?
3) Are OTC CGMs useful if you don’t have diabetes?
4) What is a “blood sugar spike,” exactly?
5) How does Abbott Lingo detect spikes?
6) Why do Stelo’s restrictions about insulin and hypoglycemia matter?
7) What’s the smartest way to use an OTC CGM without obsessing?
Frequently Asked Questions
What is Dexcom Stelo, and who is it for?
Dexcom Stelo is an FDA-cleared over-the-counter continuous glucose monitor. The FDA cleared it on March 5, 2024 for adults 18+ who are not on insulin and do not have problematic hypoglycemia. It is not designed to alert users to dangerous low blood sugar, which is why the intended population matters.
What is Abbott Lingo, and how is it positioned?
Abbott Lingo is an FDA-cleared OTC CGM positioned as a health and wellness glucose tracker for adults 18+ not on insulin. Abbott announced FDA clearance on June 10, 2024, and later announced Lingo was available in the U.S. on Sept. 5, 2024. Its marketing emphasizes behavior awareness rather than diabetes treatment.
Are OTC CGMs useful if you don’t have diabetes?
Some people may find them helpful for understanding how meals and exercise affect glucose, but major clinical voices urge caution. Harvard Health (Aug. 1, 2024) stated there is “no solid evidence” that CGMs provide value for people without diabetes. Benefits may depend on the person’s goals, risk factors, and how they interpret the data.
What is a “blood sugar spike,” exactly?
There is no single universal consumer definition of a “spike.” Clinically, post-meal rises can be normal, and interpretation depends on context. Consumer apps often define spikes using proprietary thresholds and algorithms.
How does Abbott Lingo detect spikes?
Abbott says Lingo uses a proprietary algorithm to identify “meaningful increases.” Abbott also suggests fluctuations that stay below ~100 mg/dL and don’t rise faster than ~20 mg/dL within an hour generally won’t be detected as a spike—though that is not a complete disclosure of the algorithm.
Why do Stelo’s restrictions about insulin and hypoglycemia matter?
Because Stelo is not designed to alert users to dangerous lows, it is not intended for people who need hypoglycemia protection, including many insulin users. The FDA clearance specifies adults not on insulin and without problematic hypoglycemia to reduce the risk of misuse.
